← Leaderboards
Dorina Avram
University Of Florida
$13,642,871
Attributed
$18,346,694
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,346,694 · 10
By mechanism
R01$16,733,822 · 6
R21$842,349 · 2
K01$565,409 · 1
R56$205,114 · 1
Top collaborators
- Benjamin George Keselowsky8 shared
- Hongmin Li5 shared
- Timothy Isham Shaw1 shared
Most similar at University Of Florida
Same institution · by research overlap
- David Borrego$179,675
- Benjamin George Keselowsky$10,555,340
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCytokineAutoimmune DiseasesTranscription FactorProgramsPlayT-LymphocyteMouse ModelResponseImmune ResponseCd4 Positive T LymphocytesProductionImmuneGene ExpressionMediatingIn VitroComplexInflammatoryMultiple SclerosisPathogenicityInflammationMolecularIn VivoPeripheral
Grant awards (46)
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$763,630
R01 · FY2025 · AI
Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis$740,837
R01 · FY2025 · AI
Program control of CD8+ T cell response to tumors and tumor memory$549,460
R01 · FY2025 · CA · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2024 · AI
Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis$774,914
R01 · FY2024 · AI
Tissue-Anchored vs. Circulating Engineered Enzyme Constructs for Immunometabolic Resolution of Psoriasis$798,278
R01 · FY2023 · AI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2023 · AI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$454,966
R01 · FY2023 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$787,248
R01 · FY2022 · AI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$465,213
R01 · FY2022 · AI · contact PI
High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis$813,998
R01 · FY2021 · AI
Tolerogenic dual microparticle system for treatment of multiple sclerosis$520,957
R01 · FY2021 · AI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$475,151
R01 · FY2021 · AI · contact PI
Tolerogenic dual microparticle system for treatment of multiple sclerosis$520,957
R01 · FY2020 · AI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$452,372
R01 · FY2020 · AI · contact PI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$30,001
R01 · FY2020 · AI · contact PI
Tolerogenic dual microparticle system for treatment of multiple sclerosis$520,957
R01 · FY2019 · AI
Role of Bcl11b in CD4+ T cells and innate lymphoid cells$451,846
R01 · FY2019 · AI · contact PI
Tolerogenic dual microparticle system for treatment of multiple sclerosis$520,957
R01 · FY2018 · AI
Transcriptional control of genes implicated in suppression function of Treg cells$228,750
R21 · FY2018 · AI · contact PI
Tolerogenic dual microparticle system for treatment of multiple sclerosis$520,957
R01 · FY2017 · AI
Transcriptional control of genes implicated in suppression function of Treg cells$190,625
R21 · FY2017 · AI · contact PI
Role of BCL11B in CD4+ T Cells$371,321
R01 · FY2016 · AI · contact PI
Role of BCL11B in CD4+ T Cells$372,397
R01 · FY2015 · AI · contact PI
Transcriptional control in innate lymphoid type II cells$185,974
R21 · FY2015 · AI · contact PI
Role of BCL11B in CD4+ T Cells$1
R01 · FY2015 · AI · contact PI
Role of BCL11B in CD4+ T Cells$395,000
R01 · FY2014 · AI · contact PI
Transcriptional control in innate lymphoid type II cells$237,000
R21 · FY2014 · AI · contact PI
Role of BCL11B in CD4+ T Cells$371,300
R01 · FY2013 · AI · contact PI
BCL11B in Immune Regulation$205,114
R56 · FY2013 · AI · contact PI
Role of BCL11B in CD4+ T Cells$395,000
R01 · FY2012 · AI · contact PI
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor$232,284
R01 · FY2012 · AI · contact PI
Role of BCL11B in CD4+ T Cells$377,381
R01 · FY2011 · AI · contact PI
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor$232,284
R01 · FY2011 · AI · contact PI
Role of BCL11B in CD4+ T Cells$381,193
R01 · FY2010 · AI · contact PI
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor$234,630
R01 · FY2010 · AI · contact PI
Role of BCL11B in CD4+ T Cells$385,043
R01 · FY2009 · AI · contact PI
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor$235,750
R01 · FY2009 · AI · contact PI
Role of BCL11B in CD4+ T Cells$385,043
R01 · FY2008 · AI · contact PI
Regulation of CD4 T cell Development and Function by BCL11B Transcription Factor$235,500
R01 · FY2008 · AI · contact PI
Role of BCL11B in CD4+ T Cells$392,500
R01 · FY2007 · AI · contact PI
A Novel Zinc Finger Transcriptional Modulator Of T Cells$116,127
K01 · FY2005 · AR
A Novel Zinc Finger Transcriptional Modulator Of T Cells$115,477
K01 · FY2004 · AR
A Novel Zinc Finger Transcriptional Modulator Of T Cells$112,699
K01 · FY2003 · AR
A Novel Zinc Finger Transcriptional Modulator Of T Cells$110,046
K01 · FY2002 · AR
A Novel Zinc Finger Transcriptional Modulator Of T Cells$111,060
K01 · FY2001 · AR